By Ben GlickmanShares of Fusion Pharmaceuticals rose in post-market trading on Thursday after the company had a study protocol approved by regulators. The stock was up 7.8% to $9.10, after it closed the market session up 6.8%. The updated development plan includes a Phase 2 dose optimization lead-in and a Phase 3 registrational trial, which is expected to begin in 2025. Chief Executive John Valliant said the plan outlined a path for bringing the therapy to market, if approved. Write to Ben Glickman at ben.glickman@wsj.com(END) Dow Jones NewswiresJanuary 04, 2024 18:38 ET (23:38 GMT)Copyright (c) 2024 Dow Jones & Company, Inc.

Source: Wall Street Journal January 05, 2024 11:47 UTC